Appointments at Cadence Pharmaceuticals
This article was originally published in Scrip
Cadence Pharmaceuticals (US) has appointed Dr Todd Rich to the company's board of directors and named Malcolm Lloyd-Smith senior vice-president of regulatory affairs and quality assurance. Mr Lloyd-Smith assumes the role previously held by Malvina Laudicina, who resigned from the company; he was previously vice-president and head of global regulatory affairs at Elan Pharmaceuticals. Dr Rich is vice-president of development regulatory, medical information, drug safety, quality and compliance at Genentech.
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.